Trial of promising HIV vaccine halted after failing to show benefit | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
June 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JUNE 13, 2025
Trial of promising HIV vaccine halted after failing to show benefit

World+Biz

Reuters
04 February, 2020, 09:00 am
Last modified: 04 February, 2020, 12:59 pm

Related News

  • 'Remarkable global progress': HIV cases and deaths declining
  • Pharma firm urged to share new 'game-changer' HIV drug
  • Unsafe sex in brothels is increasing HIV/AIDS exposure in Khulna
  • 'Proper Medicare can protect un-born baby from HIV'
  • Record 266 die from AIDS in Bangladesh this year

Trial of promising HIV vaccine halted after failing to show benefit

Despite the discovery of effective treatments that can put the virus in remission, experts say an HIV vaccine is critical to eradicating the virus that causes AIDS, which has infected 75 million people and killed 37.9 million globally as of 2018

Reuters
04 February, 2020, 09:00 am
Last modified: 04 February, 2020, 12:59 pm
Image credit: Cynthia Goldsmith, Centers for Disease Control and Prevention
Image credit: Cynthia Goldsmith, Centers for Disease Control and Prevention

A clinical trial testing a promising HIV vaccine in more than 5,000 people in South Africa has been halted because it failed to show a benefit, US health officials said on Monday.

The study, known as HVTN 702, built on results from the 2009 RV144 vaccine trial in Thailand, which was the first to show it was possible to prevent HIV infection in humans. In that study, the vaccine cut the rate of HIV infections by 30% compared with people who got a placebo.

"It is very disappointing that this vaccine candidate does not work, but the trial was well-conducted and got an answer as quickly as possible," Mitchell Warren, executive director of AVAC, an HIV prevention advocacy group, said in a statement.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Despite the discovery of effective treatments that can put the virus in remission, experts say an HIV vaccine is critical to eradicating the virus that causes AIDS, which has infected 75 million people and killed 37.9 million globally as of 2018.

"An HIV vaccine is essential to end the global pandemic, and we hoped this vaccine candidate would work. Regrettably, it does not," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which sponsored the study.

"Research continues on other approaches to a safe and effective HIV vaccine, which I still believe can be achieved," Fauci said in a statement.

The regimen tested in the HVTN 702 trial was adapted to target the specific subtype of HIV most prevalent in southern Africa, known as Clade C. It consisted of two vaccines - one made from GlaxoSmithKline and one from Sanofi.

The study enrolled 5,407 HIV-negative volunteers at 14 sites across South Africa. Study volunteers were sexually active men and women ages 18 to 35. They were randomly assigned to receive either the experimental vaccine regimen or a placebo. They received six shots over a period of 18 months.

Late last month, a safety board conducted an interim analysis from 2,694 study participants who got the vaccine and 2,689 volunteers who got the placebo, and found the vaccine was not effective at preventing HIV infections. Based on these findings, the NIAID stopped the trial.

The NIAID has two other late-stage HIV vaccine trials underway called Imbokodo and Mosaico. Both are testing a novel vaccine developed by Johnson & Johnson. The end of the HVTN 702 trial (also known as Uhambo) does not affect these studies or any other HIV prevention efficacy trials taking place globally, Warren said.

Top News

HIV

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographics: TBS
    Lengthy legal road ahead to repatriate Saifuzzaman's wealth from UK
  • From fact-checker to fact-checked: CA Press Wing’s turn in the hot seat
    From fact-checker to fact-checked: CA Press Wing’s turn in the hot seat
  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290

MOST VIEWED

  • Keir Starmer declines to meet CA Yunus: FT report
    Keir Starmer declines to meet CA Yunus: FT report
  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290
  • Saifuzzaman Chowdhury. Photo: Collected
    UK crime agency now freezes assets of ex-land minister Saifuzzaman: AJ
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today
  • Infofgraphics: TBS
    DGHS issues 11-point directive to prevent spread of Covid-19 in Bangladesh
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Bangladesh mulls settlements with tycoons over offshore wealth: BB governor tells FT

Related News

  • 'Remarkable global progress': HIV cases and deaths declining
  • Pharma firm urged to share new 'game-changer' HIV drug
  • Unsafe sex in brothels is increasing HIV/AIDS exposure in Khulna
  • 'Proper Medicare can protect un-born baby from HIV'
  • Record 266 die from AIDS in Bangladesh this year

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

1d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

2d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

3d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

5d | Bangladesh

More Videos from TBS

Banks' estimates were wrong: Bangladesh Bank spokesperson

Banks' estimates were wrong: Bangladesh Bank spokesperson

10h | Podcast
What exactly happened to the ill-fated Boeing aircraft?

What exactly happened to the ill-fated Boeing aircraft?

11h | TBS World
Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28

Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28

11h | TBS Insight
Curfew imposed for second night in Los Angeles

Curfew imposed for second night in Los Angeles

12h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net